U.S. Domestic Briefs: Health Challenges, Tech Advancements, and Political Upsets
Recent U.S. domestic news covers the FDA investigating deaths post-gene therapy by Sarepta, discussions at a CDC advisory panel on vaccines, persistence of patients on Wegovy and Zepbound, Boeing's oversight failures, a Pentagon radar test, and high temperatures affecting power grids. Several political events and administrative decisions were also reported.
The U.S. Food and Drug Administration is examining reports of two deceased patients with Duchenne muscular dystrophy following treatment with Sarepta Therapeutics' gene therapy, Elevidys. This has raised substantial safety concerns. Meanwhile, the CDC's vaccine advisory committee is facing scrutiny following significant staff changes initiated by Health Secretary Robert F. Kennedy Jr.
In other health news, a study reveals that a significant number of patients remain on the weight-loss drugs Wegovy and Zepbound after a year, which contrasts with previous reports. The perseverance is potentially linked to better management of side effects and improved drug availability. Meanwhile, Boeing faces criticism over inadequate safety measures related to its 737 MAX 9 aircraft from the National Transportation Safety Board.
On a global security note, the Pentagon has successfully trialed a radar system in Alaska capable of detecting potential missile threats. Extreme temperatures in U.S. cities prompted emergency measures, with electricity prices spiking in New York due to increased power demand. Additionally, Columbia University reported an IT outage incident under investigation.
(With inputs from agencies.)
- READ MORE ON:
- FDA
- CDC
- vaccines
- gene therapy
- Boeing
- Pentagon
- heat wave
- electricity
- Columbia University
- Radars
Google News